Proof of concept has been demonstrated for a modern and safe immuno-nanotherapy for prostate cancer in a study published in Experimental & Molecular Medicine. These results provide the possibility of a novel, effective treatment strategy for prostate cancer.

Using a microfluidic device, the investigators designed and synthesized a nonimmunogenic biocompatible cationic lipid nanocomplex coated with PEG (NxP). These nanoliposomes were loaded with a Cas9 guide RNA–human IL-30 complex (to delete IL30, which is known to have tumour-promoting potential and is highly expressed in prostate cancer) and then conjugated with antihuman prostate cancer-specific prostate stem cell antigen (PSCA) antibodies. These immunoliposomes are called Cas9gRNA-hIL30-hPSCA NxPs.